4 news items
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
ALGS
5 Jun 24
Title: Association of baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184±ETV
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
ACHV
ALGS
DCTH
28 May 24
potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
ALGS
22 May 24
and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184±ETV treatmentPresenter: Kha Le, PhD
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
. An estimated 1.5% to 6.5% of the global population is believed to have an ongoing inflammatory response to these excess fat deposits, which
- Prev
- 1
- Next